Company: IPGP
Filing Date: 2025-04-07
Form Type: DEF 14A
Source: 0001111928-25-000054
Chunk: 3

Company: IPG PHOTONICS CORP
Filing Date: 2025-04-07
Form: DEF 14A
Chunk 3
---
 Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Proxy Statement except for historical information are forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to accurately predict and many of which are beyond our control. As such, our actual results may differ significantly from those expressed in any forward-looking statements. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in the section titled “Risk Factors” and elsewhere in our Annual Report and other filings with the SEC. We undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. |

3

#### About IPG
| Financial Performance Highlights |

| NET SALES       |     | NET CASH FROM OPERATING ACTIVITIES |
| Welding Revenue |     | Return of Capital to Stockholders  |
|                 |     | $344M                              
 Repurchased 4.09 million shares    |

• Net sales declined 24% in 2024 due to lower industrial demand, slowdown in global investments in e-mobility and renewable energy as well as increased competition.

• Materials processing sales, which accounted for 88% of total revenue, declined 26% year over year due to lower sales across all major applications except 3D printing. Medical sales declined 15% year over year in part because of the decrease in Russian medical sales following the divestiture of our Russian subsidiary in August 2024. Advanced applications revenue decreased 3% due to lower sales in scientific and semiconductor applications, mostly offset by higher sales in government applications and instruments.

• Emerging growth products contributed 48% of total revenue in the fourth quarter of 2024, increasing compared to the 46% in the fourth quarter in prior year.

• Gross margin decreased to 35